The Centers for Medicare and Medicaid Services (CMS) said today it wants to give Medicare patients better access to cutting-edge medical devices, and that it’s willing to pay more for them beginning in fiscal year 2020. In its proposed rule, CMS said it might pay more for “certain transformative new devices” for inpatients through a […]
Respicardia
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
Respicardia launches Remedē system, taps Sommerness as CEO
Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to […]
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Zoll leads $59m Respicardia funding round
Respicardia said today it closed a $58.5 million financing round led by Zoll Medical to support commercialization efforts related to its Remede transvenous implantable neurostimulation system designed to treat patients with central sleep apnea. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the […]
Respicardia wins FDA nod for Remedē central sleep apnea neurostim device
Respicardia said today that it won FDA approval for its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea. Central Sleep Apnea occurs when the brain fails to control breathing during sleep, unlike the more common obstructive sleep apnea which consists of a partially collapsed airway which causes pauses in breathing, […]
Study: Respicardia neurostim implant shows promise in treating central sleep apnea
An implanted neurostimulator developed by Respicardia has been shown to significantly improve symptoms of central sleep apnea without serious side effects, according to a new study from the Ohio State University. Data from the study was presented at the European Society of Cardiology Congress in Rome and was published today in The Lancet. Central sleep […]
Sorin drops $20m on stake in Respicardia
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
1st patients enroll in Respicardia’s trial for sleep apnea implant
Minneapolis-based Respicardia said it launched a pivotal clinical trial of its Remede implantable device for central sleep apnea.
The pacemaker-like implant is designed to relieve sleep problems experienced by many heart failure and atrial fibrillation patients. It’s designed to send regular electrical impulses to the phrenic nerves, to prompt a response from the diaphragm.
